More tools:Markets·Screener·Research·Chat

TriSalus Life Sciences, Inc. Common Stock (TLSI) Financial Statements

TriSalus Life Sciences, Inc. Common Stock
SIC 3841 · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
FIGI BBG00Z1TKRH7
XNAS · usd
4.73▼ 0.27 (-5.40%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close5.00
Day's Range4.48 – 4.99
52-Week Range2.20 – 7.95
Volume128.9K
Avg Volume169.2K
Share Statistics
Shares Outstanding
Employees102
ExchangeXNAS
Listed2023-08-11
Share count as of August 4, 2026
Loading Income Statement…
Key questions about TriSalus Life Sciences, Inc. Common Stock (TLSI)
What is TriSalus Life Sciences, Inc. Common Stock's Market Cap?
TriSalus Life Sciences, Inc. Common Stock's Market Cap is $291.2M, based on as-reported figures from SEC (XBRL) filings.
What is TriSalus Life Sciences, Inc. Common Stock's Enterprise Value?
TriSalus Life Sciences, Inc. Common Stock's Enterprise Value is $278.0M, based on as-reported figures from SEC (XBRL) filings.
What is TriSalus Life Sciences, Inc. Common Stock's Price / Sales?
TriSalus Life Sciences, Inc. Common Stock's Price / Sales is 6.5×, based on as-reported figures from SEC (XBRL) filings.
What is TriSalus Life Sciences, Inc. Common Stock's EV / Revenue?
TriSalus Life Sciences, Inc. Common Stock's EV / Revenue is 6.2×, based on as-reported figures from SEC (XBRL) filings.
What is TriSalus Life Sciences, Inc. Common Stock's EV / EBITDA?
TriSalus Life Sciences, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is TriSalus Life Sciences, Inc. Common Stock's Revenue (TTM)?
TriSalus Life Sciences, Inc. Common Stock's Revenue (TTM) is $45.1M, based on as-reported figures from SEC (XBRL) filings.
What is TriSalus Life Sciences, Inc. Common Stock's Net Income (TTM)?
TriSalus Life Sciences, Inc. Common Stock's Net Income (TTM) is -$28.2M, based on as-reported figures from SEC (XBRL) filings.
What is TriSalus Life Sciences, Inc. Common Stock's EBITDA?
TriSalus Life Sciences, Inc. Common Stock's EBITDA is -$29.9M, based on as-reported figures from SEC (XBRL) filings.
What is TriSalus Life Sciences, Inc. Common Stock's Diluted EPS (TTM)?
TriSalus Life Sciences, Inc. Common Stock's Diluted EPS (TTM) is -0.46, based on as-reported figures from SEC (XBRL) filings.
What is TriSalus Life Sciences, Inc. Common Stock's EBITDA Margin?
TriSalus Life Sciences, Inc. Common Stock's EBITDA Margin is -66.4%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue
YoY growth+1.7%-2.9%+59.8%+57.4%
Cost of goods sold
Gross profit
% of revenue86.8%86.2%86.7%83.5%
Operating expenses:
Research and development
Sales and marketing
General and administrative
Loss from operations
% of revenue-86.0%-94.5%-24.8%-77.9%
Other income (expense)
Interest income
Interest expense
Change in fair value of SEPA, warrant and revenue base redemption liabilities
Change in fair value of contingent earnout liability
Other income (expense), net
Loss before income taxes
Income tax benefit (expense)
Net loss
% of revenue-80.5%17.3%-73.9%-93.5%
Undeclared dividends on Series A Preferred Stock
Net loss attributable to common stockholders
Basic loss per share (in dollars per share)—
Diluted loss per share (in dollars per share)—